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INTRODUCTION
Vascular endothelial growth factors (VEGF) and their tyrosine
kinase receptors (VEGF-R) are the central regulators of tumor
angiogenesis. Therefore, several angiogenesis inhibitors target-
ing the VEGF/VEGF-R pathway have been developed and have
become an important option for management of a number of human
malignancies (1, 2). However, there is increasing evidence that the
clinical results of VEGF/VEGF-R-targeted therapy are very modest,
resulting in a moderate improvement in the overall survival (3, 4).
Additionally, the clinical outcome is associated with the develop-
ment of resistance to the therapies and the increased risk for inva-
sion and metastasis (5, 6).
Several mechanisms of resistance and escape from VEGF/
VEGF-R-targeted antiangiogenesis therapy have been identified
(1,7). VEGF/VEGF-R inhibitors target vascular endothelial cells
and inhibit tumor angiogenesis, leading to hypoxia within tumor.
Therefore, it has been widely accepted that the hypoxic stress is the
central mechanism of the aggressive malignant progression of
tumor cells, including the selection of malignant cells or hypoxia-
resistant cells and the activation of malignant programs, leading to
distant metastasis (6). In fact, several preclinical studies have
shown that several VEGF pathway-targeting agents facilitate
tumor cell invasion and metastasis that required for hypoxia (8, 9).
In addition to hypoxia, there is increasing evidence that the
VEGF-R inhibitors act directly not only on endothelial cells (anti -
angiogenic function) but also on tumor cells that express functional
VEGF-R (anti -angiogenesis- independent function) (10-13).
However, the direct effects of the VEGF-R blockers on tumor cells
are not fully understood.
In this study, we examined the direct effects of VEGF-R tyrosine
kinase inhibitor, sunitinib, on evasive adaptation of colorectal
cancer cells. We found that chronic treatment with sunitinib at
pharmacologically relevant dose (14) induced the epithelial -mese-
nchymal transition (EMT) and activated cellular motility. Further-
more, the cells switched from the VEGF-R-dependent mecha-
nism to the neuropilin-1 (NRP1)-dependent one to activate their
evasive adaptation.
MATERIALS AND METHODS
Reagents, cell culture and treatment
Sunitinib (a clinical used VEGF-R tyrosine kinase inhibitor) and
V1 (an NRP-binding heptapeptide) were obtained from Selleckchem.
Human colorectal cancer cell lines (HCT116) were maintained in
RPMI1640 medium with 5% fetal bovine serum and antibiotics.
To develop the sunitinib-conditioned cells, HCT116 cells were
chronically treated with sunitinib for 5 weeks at pharmacologically
relevant concentration (0.1 μM) (14). The vehicle - treated control
cells were obtained by chronically treated with dimethyl sulfoxide
(DMSO) (0.01%) for 50 days.
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Cell migration assay
Equal numbers (50,000 cells per well) of cells were suspended in
0.25 ml of 1% RPMI1640FBS without or with bevacizumab or
sunitinib and placed in the top compartment of an uncoated 8 µm
pore membrane chambers (BD Biosciences) ; 0.75 ml of 10% RPMI
1640FBS was added to the bottom compartment. Following 24-48 h
incubation under standard conditions (37/5% CO2), non-migra-
ting cells were scraped from the top compartment, and cells that
had migrated to the bottom compartment were fixed and stained
using the Hemacolor Rapid staining of blood smear (Merck).
Membranes were excised and mounted on a standard microscope
slide. The numbers of migrated cells were determined from five
random high-power fields visualized at × 200 magnification.
Scratch wound-healing/migration assay
The scratch assay was used to further evaluate the migration
activity. Cell lines were grown in 12well plates, and when cells were
80% confluent, scratches were made on the plates using CELL
Scratcher (IWAKI). The plates were then carefully washed twice
with RPMI1640. Fresh culture medium supplemented with 1% FBS
without or with bevacizumab or sunitinib was gently added onto the
plates. The plates were allowed to incubate over the 5 days. Photo-
graphs were taken at regular intervals to monitor closure of the
gap.
Quantitative RT-PCR (qRT-PCR)
The levels of transcripts for VEGF receptors (VEGF-R1, VEGF-
R2, VEGF-R3, NRP1 and NRP2), EMT factors (E-cadherin, Slug and
Zeb1) and gapdh were measured by quantitative real time (RT)-
PCR using the following specific primer sets : VEGF-R1, 5’ -
AGAACCCCGATTATGTGAGAAA-3’ (forward) and 5’ -
GATAGATTCGGGAGCCATCC-3’ (reverse) ; VEGF-R2, 5’ -
GAACATTTGGGAAATCTCTTGC-3’ (forward) and 5’ -
CGGAAGAACAATGTAGTCTTTGC-3’ (reverse) ; VEGF-R3, 5’ -
ATAGACAAGAAAGCGGCTTCA-3’ (forward) and 5’ -
CCTCCCTTGGGAGTCAGG-3’ (reverse) ; NRP1, 5’ -
CCCTGAGAATGGGTGGACT-3’ (forward) and 5’ -
CGTGACAAAGCGCAGAAG-3’ (reverse) ; NRP-2, 5’ -
GGACCCCCAACTTGGATT-3’ (forward) and 5’ -
ATGGTTAAAAAGCGCAGGTC-3’ (reverse) ; E-cadherin, 5’ -
TGGAGGAATTCTTGCTTTGC-3’ (forward) and 5’ -
CGCTCTCCTCCGAAGAAAC-3’ (reverse) ; Slug, 5’ -
TGGTTGCTTCAAGGACACAT-3’ (forward) and 5’ -
GCAAATGCTCTGTTGCAGTG-3’ (reverse) ; Zeb1, 5’ -
CAGTGAAAGAGAAGGGAATGCT-3’ (forward) and 5’ -
CTTCAGGCCCCAGGATTT-3’ (reverse) ; gapdh, 5’ -
GCTAGGGACGGCCTGAAG-3’ (forward) and 5’ -
GCCCAATACGACCAAATCC -3’ (reverse). Amplification and quan-
tification of the PCR products were performed using the Applied
Biosystems 7500 System (Applied Biosystems). Standards were
run in the same plate and the relative standard curve method was
used to calculate the relative mRNA expression. RNA amounts
were normalized against the gapdhmRNA level.
Western blot analysis
Total cell lysates were prepared using a lysis buffer containing
100 mM Tris-HCl (pH 6.8), 300 mM NaCl, 2 mM EDTA and 4%
(v/v) SDS. Protein concentrations were determined with the BCA
protein assay (Pierce). Western immunoblotting was performed as
described previously (15) using a rabbit monoclonal anti -human E-
cadherin antibody (24E10 ; Cell Signaling Technology) at a 1/
5,000 dilution, a rabbit monoclonal anti -human Slug antibody (C
19G7 ; Cell Signaling Technology) at a 1/4,000 dilution, a rabbit
monoclonal anti -human Zeb1 antibody (D80D3 ; Cell Signaling
Technology) at a 1/4,000 dilution, a mouse monoclonal anti -human
β-actin antibody (8H10D10 ; Cell Signaling Technology) at a 1/
10,000 dilution.
Statistical analysis
Results are expressed as meansS.D. Statistical analyses of
data were done using ANOVA and the Scheffé’s test. P value0.01
was considered significant.
RESULTS
Effect of sunitinib on colorectal cancer cellmotility
We assessed the effects of sunitinib on the cell migration activity
using a modified Boyden chamber. The sunitinib-conditioned
cells showed a marked increase in migration activity (Fig. 1A). To
further confirm the results of the migration assay, the cell motility
was assessed using a scratch assay (wound healing assay). In the
scratch assay, the sunitinib-conditioned cells migrated inwardly
and covered a greater area of the scratch than the control cells
(Fig. 1B).
Effect of sunitinib on the expression of EMT-related genes
Based on the results that sunitinib activated evasive phenotype
of colorectal cancer cells, there is a possibility that the sunitinib-
conditioned cells may activate EMT gene program. Thus, we
Figure1. Effect of sunitinib on cellular migration and motility
(A) Migration of the vehicle - treated control (vehicle) and the sunitinib -
conditioned cells (sunitinib) was determined by an uncoated transwell
migration assay (n=4-5, meansSD). HPF, high power field. *P0.01,
compared with the vehicle - treated control cells.
(B) Cellular motility of the vehicle - treated control (vehicle) and the
sunitinib -conditioned cells (sunitinib) was determined by a scratch assay.
Representative photographs of the migrated cells are shown.
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examined the expression of typical EMT-related genes ; an epithe-
lial marker (E-cadherin)and mesenchymal markers (Slug and Zeb
1). We found that the expression levels of E-cadherin were signifi-
cantly decreased in the sunitinib-conditioned cells at both mRNA
and protein levels, compared to the vehicle - treated control cells
(Fig. 2A, D). In contrast, the levels of Slug and Zeb1 were elevated in
the sunitinib-conditioned cells (Fig. 2B, C, E, F). These findings
indicate that sunitinib treatment can drive the EMT, leading to
activation of cellular motility in colorectal cancer cells.
Effect of sunitinib on gene expression profile of the VEGF-R
family members
We previously reported that the chronic blockade of VEGF using
anti -VEGF antibody increases the redundant expression of VEGF-R
family members (12). Thus, we examined whether chronic inhibi-
tion of all of VEGF-R by sunitinib induces the redundant expres-
sion of VEGF-R family members (VEGFR-1, -2 and -3). The suni-
tinib-conditioned cells did not increase all of VEGF-R tested
(Fig. 3A-C), suggesting that the cells do not utilize VEGF-Rs under
the VEGF-R inhibited conditions, and that they may switch the
VEGF-R-related receptors that can bind VEGF and transduce its
signal, such as NRP1 and NRP2 (16). To test this possibility, we
determined expression levels of NRP1 and NRP2 were measured
using RT-qPCR. Expression levels of NRP1, but not NRP2, were
significantly increased in the sunitinib-conditioned cells, com-
pared to the control cells (Fig. 3D, E).
Finally, we examined the effect of NRP1 blocking on evasive
activity in the sunitinib-conditioned cells. Treatment with NRP1
antagonist significantly reduced the migratory activity in the suni-
tinib-conditioned cells, but not in the vehicle - treated control cells
(Fig. 3F). These results suggest that, under all VEGF-R inhibited
conditions by sunitinib, colorectal cancer cells switched from the
VEGF-R-dependent mechanism to the NRP1-dependent one for
adaptation to and evasion from the stress conditions.
DISCUSSION
This study focused on the direct effect of sunitinib on evasive
phenotype of colorectal cancer cells. We found that the chronic
blockade of all VEGF-R signaling by sunitinib induced EMT and
accelerated their motility. In contrast, a short exposure (1 to 2
days) to sunitinib did not activate the activities (data not shown),
indicating that the long-term inhibition of VEGF-R signaling in
tumor cells is required for the evasive adaptation. This is compat-
ible with previous preclinical studies showing that extensive treat-
ment (1 to 3 months) with sunitinib increases migration and inva-
sion in vitro and accelerates local invasion and distant metastasis in
Figure 2. Effect of sunitinib on the EMT-associated gene expression
(A-C) Expression levels of the transcripts of the epithelial maker (E-cadherin) and EMT-associated transcription factors (Slug and Zeb1) in the vehicle -
treated control (vehicle) and the sunitinib -conditioned cells (sunitinib) (n=5-6, meansSD). *P0.01, compared with the control cells.
(D-F) Representative Western blot analysis of EMT-associated protein expression levels (E-cadherin, Slug and Zeb1) in the vehicle - treated
control and the sunitinib -conditioned cells (n=3). The levels of β -actin are shown as a loading control (lower panel).
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vivo, and led to a shortening of overall survival (8, 9).
During antiangiogenic therapy, antitumor effects are caused by
reducing tumor microvessels and thus resulting hypoxic condi-
tions, which lead to tumor cell death. However, the hypoxic stress
selects a sub-population of tumor cells and activates malignant
phenotypes, including apoptosis resistance, increased survival
activity and cellular motility (6). This antiangiogenesis-dependent
and hypoxia-driven malignancy has been widely accepted in can-
cer progression, leading to invasion and metastasis (8, 9).
In addition to hypoxic stress, we revealed that sunitinib directly
acted on colorectal cancer cells and activated the EMT/migration
program via a hypoxia- independent mechanism. There is increas-
ing evidence of hypoxia- independent action of VEGF-R inhibitors
on cancer cells that accelerates their evasive and acquired resis-
tance to the therapy (10). For instance, in mouse models of glioblas-
toma multiforme, a direct inhibition of VEGF-R on cancer cells
accelerates their invasive and metastatic activities in vitro and in
vivo (17). Interestingly, Han et al demonstrate that simple hypoxic
stress is not sufficient to trigger evasive resistance, by contrast, that
targeted inhibition of VEGF-R on cancer cells induced the resis-
tance(18).
In this study, we elucidated that the sunitinib-conditioned cells
utilized NRP1 to adapt the stress conditions in which all VEGF-R
were inhibited. It seems to be reasonable, since NRP1 is a receptor
for VEGF but is not the target of sunitinib (16). There is increasing
evidence that NRP1 plays critical roles in the evasive phenotype of
several cancer cells. Overexpression of NRP1 increased migration
activities in gastric cancer cell lines and esophageal squamous cell
carcinoma cell lines (19, 20). Conversely, knockdown of NRP1 re-
duced their abilities, and it also inhibited metastasis in gastric and
lung cancer cells (19, 21). Additionally, NRP1 is preferentially ex-
pressed in metastatic MDA-MB-231 and MBA-MB-435 cells, but
not in the non-metastatic MDA-MB-453 cells (22, 23).
The possible importance of NRP1 in the tumor progression of
patients is supported by several clinical studies (24-27). Patients
with colorectal cancers expressing high levels of NRP1 showed a
significantly higher incidence of lymph node or liver metastasis
than those with tumors expressing low levels of NRP1(25). In-
creased expression of NRP1 occurs in gastrointestinal tumors, and
this upregulation appears to parallel the tumor’s invasive behavior
(24). In addition, the survival time for patients with tumors ex-
pressing high NRP1 levels was significantly shorter than for those
with low NRP1 levels (26-28). Therefore, NRP1 is suggested to be
an important target for cancer therapy.
Figure 3. Effect of sunitinib on expression profile of the VEGF-R family genes
(A-E) Expression levels of VEGF-R1 (A), VEGF-R2 (B), VEGF-R3 (C), NRP-1 (D) and NRP-2 (E) mRNA in the vehicle - treated control and the
sunitinib -conditioned cells were measured using quantitative RT-PCR (n=5, meansS.D.). *P 0.01 indicates an increased expression
compared with the vehicle - treated control cells.
(F) Effect of an NRP1 inhibition on the migration. The vehicle - treated control and the sunitinib -conditioned cells were pre - treated for 24 h with
DMSO (-) or V1 (+), and then they were analyzed migration activity, as described above (n=5, meansSD). HPF, high power field. *P0.01,
compared with the respective DMSO-treated cells.
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Collectively, we concluded that VEGF-R-targeting drug sunit-
inib directly induced evasive adaptation in colorectal cancer cells
independently of hypoxia, and NRP1 is a critical molecule to acti-
vate the adaptation under all VEGF-R inhibited conditions.
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